Filing Flows › Entrada Therapeutics (TRDA) › Q1 2025
Entrada Therapeutics (TRDA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Entrada Therapeutics (TRDA) reported revenue of $20.6M for the first quarter 2025 (Q1 2025), -65% from a year earlier and -45% from the quarter before. Operating margin was -106.0%, net loss $17.3M (84.4% of revenue).
Entrada Therapeutics, Q1 2025: revenue $20.6M (-65% year over year), operating margin -106.0%, net loss $17.3M, operating cash flow −$38.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.6M | -45% | -65% |
| Operating profit | −$21.8M | — | — |
| Net earnings | −$17.3M | — | — |
| Operating cash flow | −$38.5M | — | — |
What changed
Revenue was $20.6M in Q1 2025, down 65% year over year and down 45% from the previous quarter.
Operating costs exceeded revenue by $21.8M, an operating margin of -106.0%. Total costs grew 11% against a revenue fall of 65%. The fastest-growing cost line was Research & development (+12%). The quarter ended with a net loss of $17.3M, after a profit of $1.1M the previous quarter. Non-operating items added $4.4M, -26% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$38.5M. Non-cash charges added back $946K of depreciation and $5.1M of share-based compensation. Working capital and other items used $27.2M. Capital expenditures of $1.1M exceeded it, leaving free cash flow of −$39.7M.
Questions
What was Entrada Therapeutics' revenue in the first quarter 2025?
Entrada Therapeutics (TRDA) reported revenue of $20.6M for the first quarter 2025 (Q1 2025), -65% from a year earlier and -45% from the quarter before.
Was Entrada Therapeutics profitable in the first quarter 2025?
Operating loss was $21.8M (-106.0% of revenue) and net loss $17.3M.